Sigimedtech Signs Exclusive Supply Agreement with DePuy Synthes for 'Novosis Trauma'
First Overseas Supply Milestone Achieved Through Global Network Collaboration
Sigimedtech, a company specializing in the research and manufacturing of orthopedic and dental implants, announced on June 5 that it has signed an exclusive supply agreement with DePuy Synthes, a global orthopedic solutions company, for 'Novosis Trauma' in the Malaysian market.
Under this agreement, DePuy Synthes will be responsible for the exclusive distribution and sales of Novosis Trauma products in Malaysia. Sigimedtech will support the expansion of its local market presence by providing a stable supply and production system.
Novosis Trauma is a bone regeneration solution that combines a hydroxyapatite-based synthetic bone matrix with recombinant human bone morphogenetic protein-2 (rhBMP-2). The product is designed to induce bone formation in cases of traumatic fractures and bone defects. It is used for bone union and regeneration in orthopedic trauma treatment and is expanding its potential applications in the field of complex bone defect treatment.
This contract is particularly significant as it marks Sigimedtech's first overseas supply case based on a strategic collaboration with a global healthcare company. Through this agreement, Sigimedtech has been able to demonstrate the competitiveness of its rhBMP-2-based bone regeneration technology and its potential for global commercialization.
Malaysia is considered one of the fastest-growing markets in Southeast Asia for orthopedic and trauma care. The company plans to expand product accessibility and market recognition by leveraging its partner's local hospital network and distribution capabilities. Furthermore, starting with this agreement, Sigimedtech aims to expand its supply focus to Asian and Oceania markets, while also considering additional collaborations in the Middle East and other global markets in the future.
Currently, the two companies are coordinating local sales forecasts and supply schedules, and will gradually increase the supply volume in response to market conditions and rising demand.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Yoo Hyunseung, CEO of Sigimedtech, stated, "This agreement is a meaningful example of verifying the product competitiveness and overseas commercialization potential of Novosis Trauma through collaboration with a global healthcare company. Based on our partner's global network and Sigimedtech's bone regeneration technology, we will expand our overseas supply base and strengthen our competitiveness in the global orthopedic trauma care market."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.